查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1581227

核酸药物市场：按核酸类型、药物传输、治疗应用和最终用户划分 - 2025-2030 年全球预测

Nucleic Acid-Based Drugs Market by Nucleic Acid Type (DNA-based Drugs, RNA-based Drugs), Drug Type (Long-Chain Nucleic Acid Drugs, Short-Chain Nucleic Acid Drugs), Method of Delivery, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年核酸药物市值为47.6亿美元，预计到2024年将达到54.6亿美元，复合年增长率为15.09%，到2030年将达到127.4亿美元。

核酸药物是源自天然或合成核酸（例如DNA、RNA、适体和寡核苷酸）的治疗剂，用于透过靶向特定的分子机制来治疗各种遗传性感染疾病。这种需求源自于其直接改变基因表现的能力，提供高度标靶化的治疗，与传统药物相比，副作用可能较少。这些药物在基因治疗、反义治疗和RNA干扰等领域有应用，有助于癌症、心血管和感染疾病治疗等最终用途领域。基因研究的进步、药物输送系统的技术创新以及个人化医疗投资的增加推动了核酸药物市场的发展。关键的成长要素包括遗传性疾病盛行率的上升、开发针对 COVID-19 等病毒感染疾病的治疗方法的迫切性，以及强大的标靶治疗标记产品线。新的商机正在将应用扩展到肿瘤学之外，包括在神经退化性疾病疾病和代谢疾病方面的巨大潜力。为了利用这些机会，公司应该投资加强药物输送机制，以提高核酸药物的稳定性和吸收率，并在药物开发过程中利用人工智慧。然而，高昂的开发成本、复杂的法律规范、向目标细胞递送的挑战以及潜在的脱靶效应等限制构成了主要障碍。智慧财产权的排他性和产品的特殊性也限制了市场的扩张。非病毒传递方法的创新，例如奈米颗粒和缀合技术，是有前景的研究和业务成长领域。生物技术公司和研究机构之间的合作也可能带来突破，解决当前的交付和稳定性挑战。该市场的特点是快速发展，强调了敏捷反应和持续投资研发以推进核酸疗法并充分发挥其治疗潜力的重要性。

主要市场统计
基准年[2023] 47.6亿美元
预测年份 [2024] 54.6亿美元
预测年份 [2030] 127.4亿美元
复合年增长率（%） 15.09%

市场动态：揭示快速发展的核酸药物市场的关键市场洞察

核酸药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球慢性病流行
    • 对个人化医疗的认识和接受度不断提高
  • 市场限制因素
    • 基于核酸的疗法成本高昂
  • 市场机会
    • 扩大核酸药物在罕见遗传疾病治疗的应用
    • 製药和生技公司之间的合作不断加强
  • 市场挑战
    • 确保核酸药物稳定性和传递的局限性

波特五力：驾驭核酸药物市场的策略工具

波特的五力架构是了解核酸药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解核酸药物市场的外部影响

外部宏观环境因素对核酸药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解核酸药物市场竞争态势

对核酸药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵核酸药物市场供应商绩效评估

FPNV定位矩阵是评估核酸药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了核酸药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对核酸药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地慢性病的盛行率不断上升
      • 对个人化医疗的认识和接受度不断提高
    • 抑制因素
      • 基于核酸的疗法高成本
    • 机会
      • 扩大核酸药物在罕见遗传疾病治疗的应用
      • 製药和生物技术公司之间合作的演变
    • 任务
      • 确保核酸药物稳定性和传递的局限性
  • 市场区隔分析
    • 核酸类型：标靶遗传物质的特异性和效率为基于 RNA 的药物带来了新的应用。
    • 治疗应用：核酸药物在神经系统疾病的多样化应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 核酸药物市场（依核酸类型划分）

  • 基于DNA的医学
  • 基于RNA的医学

第七章 核酸药物市场（依药物类型）

  • 长链核酸药物
  • 短链核酸药物

第八章以递送方式分類的核酸药物市场

  • 在地化交付
  • 全身给药

第九章基于治疗应用的核酸药物市场

  • 心血管疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学
  • 罕见疾病和遗传疾病

第10章基于核酸的药物市场：依最终用户分类

  • 生物製药公司
  • 医院/诊所
  • 调查机构

第十一章 美洲核酸药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区核酸药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲核酸药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • GlaxoSmithKline Plc)以 5,000 万美元收购 Elsie Biotechnologies，作为加速核酸药物开发策略倡议的一部分。
    • 沃特世公司推出先进的 SEC管柱来加速基因为基础的药物开发。
    • 旭化成生物製程公司 (Asahi Kasei Bioprocess) 与 Axolabs GmbH 合作加速创新基因疗法的开发
  • 战略分析和建议

公司名单

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Beam Therapeutics Inc.
  • BioMarin Pharmaceutical Inc.
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dicerna Pharmaceuticals, Inc.
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Evotec SE
  • Generation Bio Co.
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc
  • Sarepta Therapeutics, Inc.
  • Senti Biosciences, Inc.
  • Silence Therapeutics Plc
  • Stoke Therapeutics, Inc.
  • Translate Bio, Inc. by Sanofi SA
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market was valued at USD 4.76 billion in 2023, expected to reach USD 5.46 billion in 2024, and is projected to grow at a CAGR of 15.09%, to USD 12.74 billion by 2030.

Nucleic acid-based drugs are therapeutic agents derived from natural or synthetic nucleic acids, such as DNA, RNA, aptamers, and oligonucleotides, aimed at treating a variety of genetic and infectious diseases by targeting specific molecular mechanisms. Their necessity arises from their ability to directly alter genetic expression, offering highly targeted treatments with potentially fewer side effects compared to traditional drugs. These drugs are applied in areas like gene therapy, antisense therapy, and RNA interference, serving end-use sectors including oncology, cardiovascular, and infectious disease treatment, among others. The market for nucleic acid-based drugs is being fueled by advances in genetic research, technological innovations in drug delivery systems, and increasing investment in personalized medicine. Key growth factors include rising prevalence of genetic disorders, urgency in developing treatments for viral infections like COVID-19, and robust pipelines of biomarkers for targeted therapies. Emerging opportunities lie in expanding applications beyond oncology, with significant potential in neurodegenerative and metabolic disorders. To capitalize on these opportunities, companies should invest in enhancing delivery mechanisms to improve the stability and uptake of nucleic acid drugs and leverage artificial intelligence in drug development processes. However, limitations such as high development costs, complex regulatory frameworks, challenges in delivery to target cells, and potential off-target effects pose significant hurdles. The exclusivity of intellectual property and product specificity also restrict market expansion. Innovations in non-viral delivery methods, like nanoparticles and conjugation technologies, represent promising areas for research and business growth. Collaborations between biotech firms and research institutions can also spark breakthroughs in solving current delivery and stability challenges. The market is characterized by rapid developments, emphasizing the importance of agility and sustained investment in R&D to drive forward nucleic acid-based therapies and fully exploit their therapeutic potential.

KEY MARKET STATISTICS
Base Year [2023] USD 4.76 billion
Estimated Year [2024] USD 5.46 billion
Forecast Year [2030] USD 12.74 billion
CAGR (%) 15.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid-Based Drugs Market

The Nucleic Acid-Based Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of chronic diseases across the globe
    • Rising awareness and acceptance of personalized medicine
  • Market Restraints
    • High costs of nucleic acid-based therapies
  • Market Opportunities
    • Expanding applications of nucleic acid-based drugs in treating rare genetic disorders
    • Evolving collaboration between pharmaceutical companies and biotechnology firms
  • Market Challenges
    • Limitations in ensuring the stability and delivery of nucleic acid-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid-Based Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid-Based Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid-Based Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid-Based Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid-Based Drugs Market

A detailed market share analysis in the Nucleic Acid-Based Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid-Based Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid-Based Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid-Based Drugs Market

A strategic analysis of the Nucleic Acid-Based Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid-Based Drugs Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., Beam Therapeutics Inc., BioMarin Pharmaceutical Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, CureVac N.V., Dicerna Pharmaceuticals, Inc., Dynavax Technologies Corporation, Editas Medicine, Inc., Evotec SE, Generation Bio Co., Ionis Pharmaceuticals, Inc., Moderna, Inc., ProQR Therapeutics N.V., Sangamo Therapeutics, Inc, Sarepta Therapeutics, Inc., Senti Biosciences, Inc., Silence Therapeutics Plc, Stoke Therapeutics, Inc., Translate Bio, Inc. by Sanofi SA, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid-Based Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Nucleic Acid Type, market is studied across DNA-based Drugs and RNA-based Drugs.
  • Based on Drug Type, market is studied across Long-Chain Nucleic Acid Drugs and Short-Chain Nucleic Acid Drugs.
  • Based on Method of Delivery, market is studied across Localized Delivery and Systemic Delivery.
  • Based on Therapeutic Application, market is studied across Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Oncology, and Rare & Genetic Disorders.
  • Based on End-User, market is studied across Biopharmaceutical Companies, Hospitals & Clinics, and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases across the globe
      • 5.1.1.2. Rising awareness and acceptance of personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of nucleic acid-based therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding applications of nucleic acid-based drugs in treating rare genetic disorders
      • 5.1.3.2. Evolving collaboration between pharmaceutical companies and biotechnology firms
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in ensuring the stability and delivery of nucleic acid-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Nucleic Acid Type: Emerging application of RNA-based drugs owing to specificity and efficiency in targeting genetic material
    • 5.2.2. Therapeutic Application: Diverse applications of nucleic acid-based drugs in neurological disorders
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid-Based Drugs Market, by Nucleic Acid Type

  • 6.1. Introduction
  • 6.2. DNA-based Drugs
  • 6.3. RNA-based Drugs

7. Nucleic Acid-Based Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Long-Chain Nucleic Acid Drugs
  • 7.3. Short-Chain Nucleic Acid Drugs

8. Nucleic Acid-Based Drugs Market, by Method of Delivery

  • 8.1. Introduction
  • 8.2. Localized Delivery
  • 8.3. Systemic Delivery

9. Nucleic Acid-Based Drugs Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
  • 9.4. Neurological Disorders
  • 9.5. Oncology
  • 9.6. Rare & Genetic Disorders

10. Nucleic Acid-Based Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Biopharmaceutical Companies
  • 10.3. Hospitals & Clinics
  • 10.4. Research Organizations

11. Americas Nucleic Acid-Based Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Nucleic Acid-Based Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GlaxoSmithKline PLC acquired Elsie Biotechnologies, LLC for USD 50 Million in a strategic move to boost nucleic acid drug development
    • 14.3.2. Waters Corporation introduced advanced SEC columns to accelerate gene-based drug development
    • 14.3.3. Asahi Kasei Bioprocess and Axolabs GmbH partner to accelerate the development of innovative gene-based therapies
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Arcturus Therapeutics Holdings Inc.
  • 3. Arrowhead Pharmaceuticals, Inc.
  • 4. Beam Therapeutics Inc.
  • 5. BioMarin Pharmaceutical Inc.
  • 6. Bluebird Bio, Inc.
  • 7. CRISPR Therapeutics AG
  • 8. CureVac N.V.
  • 9. Dicerna Pharmaceuticals, Inc.
  • 10. Dynavax Technologies Corporation
  • 11. Editas Medicine, Inc.
  • 12. Evotec SE
  • 13. Generation Bio Co.
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. Moderna, Inc.
  • 16. ProQR Therapeutics N.V.
  • 17. Sangamo Therapeutics, Inc
  • 18. Sarepta Therapeutics, Inc.
  • 19. Senti Biosciences, Inc.
  • 20. Silence Therapeutics Plc
  • 21. Stoke Therapeutics, Inc.
  • 22. Translate Bio, Inc. by Sanofi SA
  • 23. Voyager Therapeutics, Inc.
  • 24. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID-BASED DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LONG-CHAIN NUCLEIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT-CHAIN NUCLEIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LOCALIZED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SYSTEMIC DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023